Advancing Frontline Treatment in Metastatic Triple-Negative Breast Cancer with ADCs

This video was supported by Gilead Sciences, Inc., but editorially independently created by the Oncology Nursing News team.

NP Theresa Stukus and NP Nelli Zafman discuss how the high rate of attrition between first- and second-line therapy has fundamentally changed treatment decision-making in metastatic triple-negative breast cancer (mTNBC). NP Zafman emphasizes that because many patients may never receive subsequent therapy, selecting the most appropriate first-line treatment has become increasingly important. The conversation then shifts to the evolving role of antibody-drug conjugates (ADCs) in the frontline setting, highlighting how recent clinical evidence has expanded treatment options beyond conventional chemotherapy. The faculty review how emerging frontline ADC data has contributed to improvements in clinical outcomes, particularly progression-free survival, and discuss how these advances are reshaping the treatment paradigm for patients with mTNBC. Together, they underscore the importance of incorporating the latest evidence into individualized treatment planning while considering each patient's disease characteristics, prognosis, and therapeutic goals.